Q-omics provides the consensus-scored BMPER profile across patient tissues and cancer cell-line models. BMPER expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, BMPER is differentially expressed in 15, with the highest sampling consensus in LUAD. Additionally, BMPER RNA expression shows 17,492 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight OV, LUAD, and UVM as cancer lineages where BMPER shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BMPER — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BMPER survival associations across molecular data types. BMPER RNA expression shows survival associations in the most cancer types (27), followed by mutation status (11) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BMPER RNA expression–survival associations across cancer types. High BMPER expression shows unfavorable associations in OV, BLCA, HNSC and CESC, but favorable associations in PAAD and LAML. The OV Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify OV as the clearest survival context for BMPER RNA expression.
This table summarizes BMPER tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 3. The strongest signals are observed in LUAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for BMPER. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BMPER shows lower tumor expression in LUAD, BLCA, LUSC, LIHC, UCEC and COAD. The LUAD box plot shows higher BMPER RNA expression in normal versus tumor tissue (log2 FC = −2.217, t-test p < 0.001).
This table shows molecular features associated with BMPER in patient tissues and cancer cell lines. In patient samples, BMPER shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, BMPER RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
